Clinical trials: Steroid Refractory Acute Graft Versus Host Disease
Chronic Graft vs. Host Disease, Graft vs Host Disease
Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD
Background: Some allogeneic stem cell transplant recipients get acute graft-versus-host disease (GVHD). They always get steroids as the first treatment, but this may not work.
- Conditions
- Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
- Trial name
- NCT02322190
- Testing
- Extracorporeal Photopheresis (ECP), Methoxsalen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
The immune system has offensive and defensive capacities. In bone marrow transplantation, offensive cells in the donor grafts may attack host's organs, leading to a complication known as Graft versus Host Disease (GVDH).
- Conditions
- Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Steroid Refractory Graft-Versus-Host Disease
- Trial name
- NCT01903473
- Testing
- Rapamycin, T regulatory cells
- Where
- 2 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- University of Liege
Graft-versus-host-disease
Treatment of Steroid Resistant GVHD by Infusion MSC
For numerous malignant diseases allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy. One of the major complications is the occurrence of acute graft-versus-host-disease (aGVHD).
- Trial name
- MSCforGVHD (NCT00827398)
- Testing
- MSC (hPPL)
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- N.M. Wulffraat
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
MaaT013 showed interesting results in steroids and ruxolitinib-resistant aGVHD patients with gut involvement (55% ORR at D28) and 47% and 39% OS at 6 and 12 months respectively (Malard 2020), therefore warrant being tested as…
- Trial name
- ARES (NCT04769895)
- Testing
- MaaT013
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 66 people
- Sponsor
- MaaT Pharma
GVHD,Acute, Stem Cell Transplant Complications
MAP-guided Preemptive Therapy of aGvHD
Acute graft versus host disease (aGvHD) is a severe and potentially fatal complication of allogeneic hematopoietic stem cell transplantation (HCT).
- Trial name
- NCT05368181
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sichuan University
Graft Versus Host Disease
Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD
The purpose of this study is to see if two treatments (extracorporeal photopheresis and Mesenchymal Stromal Cell (MSC) infusion, can be given safely together, and if they improve the symptoms of a Graft versus Host Disease…
- Trial name
- NCT05333029
- Testing
- Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
- Where
- United States
- Sponsor
- Molly Gallogly
Acute Graft Versus Host Disease
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
Phase II efficacy evaluation, phase I/II efficacy and toxicity trial of recombinant human keratinocyte growth factor for the treatment of steroid refractory gastrointestinal graft versus host disease.
- Trial name
- NCT00038792
- Testing
- Recombinant Human Keratinocyte Growth Factor
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)
A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)
The researchers are doing this study to find out whether the combination of LBP-MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) and ruxolitinib is a safe treatment for people with graft-versus-host disease…
- Trial name
- NCT07913672
- Testing
- Ruxolitinib, LBP- MARCO
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
GVHD, Acute Stem Cell Transplant Complications
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
The goal of this observation study is to test in patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT06075225
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sichuan University
Graft vs Host Disease
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
This clinical trial will study the safety and efficacy of using the drug Zemaira, an Alpha 1-Antitrypsin (AAT) medication (also known as an Alpha1-Proteinase Inhibitor [Human]) for the treatment of steroid refractory GVHD.
- Trial name
- NCT01700036
- Testing
- Alpha-1-Antitrypsin (AAT)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Hematological Malignancy, GVHD - Graft-Versus-Host Disease
Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.
Study Design Prospective, single center, single arm, Phase II study. Research aims and objectives Aim: To evaluate the efficacy and safety of standardized Withaferin A in steroid refractory acute GvHD in patients post allogeneic…
- Conditions
- Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory
- Trial name
- Withaferin_A (NCT07708987)
- Testing
- Standardized Withaferin A (SWA)
- Where
- India
- Volunteers
- 34 people
- Sponsor
- Tata Memorial Centre
Steroid-refractory Acute Graft-versus-host Disease
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or…
- Trial name
- BALDER (NCT06075706)
- Testing
- MC0518, BAT
- Where
- 36 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- medac GmbH
Graft-versus-Host Disease
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
The purpose of this research study is to test the safety and effectiveness of VELCADE® in the treatment of acute graft-versus-host disease (GVHD) that has not responded to steroids or has worsened when the steroid dose was…
- Trial name
- NCT00408928
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Steroid Refractory GVHD
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05663827
- Testing
- Ruxolitinib
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Yi-Lun Wang
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
MaaT013 is still in clinical development phase and is not approved yet for marketing in any region. During the development program, MaaT Pharma has undertaken initial development with closely related product candidates, leading…
- Trial name
- ATLAS (NCT04768907)
- Testing
- MaaT013
- Where
- 46 sites in Austria, Belgium and 6 more
- Sponsor
- MaaT Pharma
Multiple Sclerosis, Multiple Sclerosis, Acute Relapsing
Plasma Exchanges in Multiple Sclerosis (MS) Relapses
In more than 40 % of multiple sclerosis (MS) patients experiencing relapse, residual disability accumulates in spite of steroid treatment.
- Trial name
- PLASMASEP (NCT01442233)
- Testing
- plasma exchange
- Where
- 6 sites in France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
Graft vs Host Disease
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior efficacy compared with ruxolitinib monotherapy in patients with severe…
- Trial name
- RESCUE (NCT07184853)
- Testing
- Ruxolitinib (JAKAVI®), Etanercept (Enbrel)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Graft Versus Host Disease
Identification of Novel Targetable Kinases in SR-a GvHD
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
- Trial name
- NCT04342442
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Acute Graft Versus Host Disease
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host…
- Trial name
- NCT03158896
- Testing
- MSCTC-0010 Dose Escalation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Kansas Medical Center